Human therapeutics company Amgen (NASDAQ:AMGN) disclosed on Friday the receipt of approval from the US Food and Drug Administration (FDA) for AVSOLA (infliximab-axxq) for all the same approved indications of the reference product Remicade (infliximab) across inflammation portfolios.
The US FDA has approved the company's AVSOLA (infliximab-axxq) for the treatment of moderate-to-severe rheumatoid arthritis (RA), moderate-to-severe Crohn's Disease (CD) in the adult and paediatric population, moderate-to-severe ulcerative colitis (UC) in the adult and paediatric population, chronic severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS).
According to the company, AVSOLA is a biosimilar to Remicade, an anti-tumour necrosis factor alpha (anti-TNF) monoclonal antibody. The active ingredient of AVSOLA is an anti-TNF monoclonal antibody that has the same amino acid sequence as Remicade. AVSOLA also has the same pharmaceutical dosage form and strength as Remicade. AVSOLA is currently not available
In conjunction, the company's randomised, double-blind comparative clinical study evaluated the efficacy and safety of AVSOLA compared to Remicade in patients with moderate-to-severe RA. There were 558 patients enrolled and randomised (1:1) to receive either AVSOLA or Remicade at a dose of 3 mg/kg administered as an infusion on day one, at weeks two and six, and every eight weeks thereafter.
Under the company's the company's randomized, double-blind comparative clinical study, the primary endpoint was the response difference (RD) of 20% improvement in American College of Rheumatology core set measurements (ACR20) at week 22.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial